Bicocca Open Archive

Logo unimib boa
CARBONE, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.637
AS - Asia 10.065
EU - Europa 9.516
SA - Sud America 1.534
AF - Africa 262
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 6
Totale 36.039
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.716
SG - Singapore 3.655
SE - Svezia 2.578
IT - Italia 2.220
CN - Cina 1.914
HK - Hong Kong 1.385
VN - Vietnam 1.344
RU - Federazione Russa 1.187
BR - Brasile 1.128
DE - Germania 1.035
CA - Canada 772
IE - Irlanda 619
GB - Regno Unito 469
BD - Bangladesh 341
FR - Francia 335
IN - India 308
KR - Corea 171
NL - Olanda 161
AR - Argentina 156
TR - Turchia 155
AT - Austria 152
UA - Ucraina 141
FI - Finlandia 132
IQ - Iraq 122
ID - Indonesia 115
CH - Svizzera 98
ES - Italia 85
JP - Giappone 82
PL - Polonia 82
ZA - Sudafrica 80
PK - Pakistan 78
MX - Messico 77
EC - Ecuador 67
PH - Filippine 63
DK - Danimarca 56
SA - Arabia Saudita 48
VE - Venezuela 47
MY - Malesia 46
CO - Colombia 44
UZ - Uzbekistan 34
MA - Marocco 33
EG - Egitto 27
BE - Belgio 24
JO - Giordania 24
CL - Cile 23
LT - Lituania 23
PY - Paraguay 23
DZ - Algeria 21
AZ - Azerbaigian 20
KE - Kenya 20
IL - Israele 19
ET - Etiopia 18
RO - Romania 18
JM - Giamaica 17
PT - Portogallo 17
TW - Taiwan 17
PE - Perù 15
TN - Tunisia 15
AU - Australia 14
BO - Bolivia 14
CR - Costa Rica 14
NP - Nepal 14
UY - Uruguay 14
AE - Emirati Arabi Uniti 13
TH - Thailandia 13
CZ - Repubblica Ceca 12
RS - Serbia 12
OM - Oman 11
PS - Palestinian Territory 11
AL - Albania 10
SN - Senegal 9
SY - Repubblica araba siriana 9
BG - Bulgaria 8
GR - Grecia 8
PA - Panama 8
KZ - Kazakistan 7
SK - Slovacchia (Repubblica Slovacca) 7
AO - Angola 6
DO - Repubblica Dominicana 6
HN - Honduras 6
IR - Iran 6
CI - Costa d'Avorio 5
GT - Guatemala 5
HU - Ungheria 5
LA - Repubblica Popolare Democratica del Laos 5
MM - Myanmar 5
BA - Bosnia-Erzegovina 4
BY - Bielorussia 4
GE - Georgia 4
GH - Ghana 4
LB - Libano 4
MU - Mauritius 4
NZ - Nuova Zelanda 4
QA - Qatar 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
CG - Congo 3
KG - Kirghizistan 3
KH - Cambogia 3
MD - Moldavia 3
Totale 35.981
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.274
Singapore 1.995
Stockholm 1.892
Hong Kong 1.337
Ashburn 1.076
San Jose 993
Frankfurt am Main 755
Fairfield 634
Toronto 631
Dublin 597
Milan 577
Chandler 570
Woodbridge 486
Wilmington 478
Chicago 465
New York 448
Ho Chi Minh City 410
Houston 399
Santa Clara 360
Los Angeles 343
Dallas 328
Hanoi 323
Hefei 296
Seattle 267
Beijing 264
Dearborn 252
The Dalles 226
Cambridge 225
Princeton 215
Boardman 163
Lauterbourg 159
Seoul 153
London 152
Jacksonville 148
Rome 147
Buffalo 146
Shanghai 139
Council Bluffs 125
Vienna 121
São Paulo 112
Nanjing 111
Moscow 105
Lawrence 103
Altamura 101
Zurich 84
Orem 73
San Diego 73
Munich 71
Jakarta 67
Helsinki 65
Tokyo 59
Warsaw 51
Florence 48
Haiphong 48
Baghdad 47
Monza 47
Nuremberg 46
Columbus 45
Rio de Janeiro 44
Turin 43
Da Nang 42
Johannesburg 42
Denver 39
Montreal 36
Phoenix 35
Atlanta 33
Brooklyn 33
Guangzhou 33
Paris 33
Salt Lake City 32
Amsterdam 31
Biên Hòa 31
Chennai 30
Mumbai 30
Andover 29
Lachine 29
Naples 28
Pune 28
Tashkent 28
Lissone 27
Nanchang 27
Poplar 27
Tianjin 27
Bari 26
Boston 26
Genoa 24
Hải Dương 24
Guayaquil 23
Hangzhou 23
Istanbul 23
New Delhi 23
Ottawa 23
Quito 23
Elk Grove Village 22
Amman 21
Bologna 21
Brussels 21
Can Tho 21
Changsha 21
San Francisco 21
Totale 23.128
Salva come PNG Salva come JPEG
Nome #
Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial 1.964
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 589
The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis 467
Exploring the landscape of steatotic liver disease in the general US population 433
A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude? 432
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 408
Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid 389
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 388
Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak 366
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response 353
Endocrinology and Metabolic Diseases (Including Diabetes) 342
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 342
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 340
Autoimmune liver disease, autoimmunity and liver transplantation 340
Risk stratification in primary sclerosing cholangitis 334
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 334
Precision medicine in primary biliary cholangitis 328
Liver Transplantation in Alcohol-Associated Hepatitis. Benefits and Limitations of Psychosocial Selection and Support in Alcohol Relapse. The Experience of a Tertiary Center in Italy 325
Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation 321
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 319
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 318
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 316
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 307
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls 306
Autoimmune liver diseases 294
A NOVEL MACHINE-LEARNING, COMMON VARIANTS-BASED APPROACH TO PREDICT PRIMARY BILIARY CHOLANGITIS 294
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 293
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 292
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis 287
New Therapeutic Targets in Autoimmune Cholangiopathies 284
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 279
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis 276
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 273
The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence 272
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland 268
Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis 264
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 262
The challenges of primary biliary cholangitis: What is new and what needs to be done 259
Artificial Intelligence and liver: Opportunities and barriers 258
Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 255
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 253
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach 252
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 251
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 247
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 243
Prognostic models in primary biliary cholangitis 241
Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature 237
Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis 235
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? 234
Reply to: “A spotlight on natural killer cells in primary biliary cholangitis” 234
Artificial intelligence for precision medicine in autoimmune liver disease 233
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 233
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 233
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe 229
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers 229
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis 228
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 227
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis 226
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 226
Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score 225
Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records 224
Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency 224
Comprehensive review of autoantibodies in patients with hyper-IgM syndrome 221
Genetics and epigenetics of primary biliary cirrhosis 219
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis 217
Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis 215
Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement 214
Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study 212
Primary sclerosing cholangitis: Burden of disease and mortality using data from the national rare diseases registry in Italy 205
Primary Sclerosing Cholangitis and Amyloid A Amyloidosis: Association or Coincidence? 204
Geoepidemiology, Genetic and Environmental Risk Factors for PBC 204
Leptin attenuates ischemia-reperfusion injury in the rat liver 203
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 201
Hepatitis C virus and nonliver solid organ transplantation 201
Corrigendum to: “An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs” [J Hepatol 75 (2021) 572-581, (S0168827821003342), (10.1016/j.jhep.2021.04.055)] 200
The immunobiology of female predominance in primary biliary cholangitis 200
Non-invasive imaging biomarkers in chronic liver disease 198
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma 198
Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation 197
The phenotypic landscape of primary biliary cholangitis and autoimmune hepatitis variants 196
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 196
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States 194
Treatment discontinuation with peg-interferon: What to consider 194
Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study 192
Cell and organ bioengineering technology as applied to gastrointestinal diseases 191
Treatment of PBC-A step forward 190
How regenerative medicine and tissue engineering may complement the available armamentarium in gastroenterology? 189
An update on novel pharmacological agents for primary sclerosing cholangitis 186
Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis 185
Late acute liver allograft rejection; A study of its natural history and graft survival in the current era 185
Cost of illness of Primary Biliary Cholangitis - a population-based study 185
Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono-Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study 184
Open challenges in the management of autoimmune hepatitis 179
Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis 179
The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort 176
Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history 175
LLM-PBC: Logic Learning Machine-Based Explainable Rules Accurately Stratify the Genetic Risk of Primary Biliary Cholangitis 174
European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care 173
The "gut microbiota" hypothesis in primary sclerosing cholangitis 172
Primary Biliary Cholangitis: advances in management and treatment of the disease 171
Totale 27.310
Salva come PNG Salva come JPEG
Categoria #
all - tutte 122.389
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122.389
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021196 0 0 0 0 0 0 0 0 0 0 0 196
2021/20221.871 193 187 214 143 141 142 54 105 79 145 170 298
2022/20232.934 333 740 266 252 264 370 126 130 222 76 83 72
2023/20242.687 71 111 108 258 293 580 383 76 156 173 93 385
2024/20256.364 445 717 389 347 506 216 322 290 669 813 685 965
2025/202616.982 1.534 958 1.171 1.569 1.502 792 2.095 867 1.300 3.327 1.202 665
Totale 36.915